CJC-1295, Ipamorelin, Sermorelin and GHRP-6 Under the 2026 WADA List
An athlete-focused overview of CJC-1295, ipamorelin, sermorelin and GHRP-6 under the 2026 anti-doping framework.
Executive Summary
WADA's Prohibited List addresses growth-hormone-releasing factors and related secretagogues. Athletes must evaluate CJC-1295, sermorelin, ipamorelin and GHRP-6 under the current list and their sport's rules. A substance can be prohibited even if it is not FDA approved, and a prescription does not automatically permit its use in sport.
Where the Compounds Fit
| Compound | Functional family | Anti-doping concern |
|---|---|---|
| CJC-1295 | GHRH analogue/releasing factor | GH-releasing factor category |
| Sermorelin | GHRH analogue | GH-releasing factor category |
| Ipamorelin | Ghrelin-receptor secretagogue | GH secretagogue category |
| GHRP-6 | Growth-hormone-releasing peptide | GH secretagogue category |
Why Labels Are Not Enough
Online products may use aliases, mixtures or incomplete ingredient descriptions. Strict-liability rules generally place responsibility on the athlete for substances found in a sample. Contamination and inaccurate labeling add risk rather than create an exemption.
Therapeutic Use Exemptions
A TUE is not created by a clinic recommendation or prescription alone. Eligibility, documentation, timing and approval are governed by the relevant anti-doping organization. Athletes need case-specific guidance before use.
Verification Steps
- Read the current Prohibited List and effective date.
- Check the national anti-doping organization and sport federation.
- Search every active ingredient and recognized synonym.
- Do not assume medical records convert prohibited use into permitted use.